Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hancock

Showing results (541-550 of 557) with videos related to

Pageof 56
Sort By:
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|June 2, 2005
Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophreniaG B Fox, T A Esbenshade, J B Pan, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 21, 2012
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonistTimothy A Esbenshade, Kaitlin E Browman, Thomas R Miller, et al.
Science Translational Medicine|November 19, 2016
The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicityMichal Wieczorek, Joseph Tcherkezian, Cynthia Bernier, et al.
Journal of Medicinal Chemistry|September 25, 2008
Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligandsRobert J Altenbach, Ronald M Adair, Brian M Bettencourt, et al.
Plos Computational Biology|April 23, 2020
Vector bionomics and vectorial capacity as emergent properties of mosquito behaviors and ecologySean L Wu, Héctor M Sánchez C, John M Henry, et al.
Biochemical Pharmacology|March 21, 2007
Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activityMarlon Cowart, Gregory A Gfesser, Kaitlin E Browman, et al.
Breast Cancer Research and Treatment|December 3, 2013
Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencingMilan Radovich, Susan E Clare, Rutuja Atale, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 21, 2004
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonistGerard B Fox, Timothy A Esbenshade, Jia Bao Pan, et al.
Journal of Neuroimmunology|April 13, 2010
Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosisK C O'Connor, C Lopez-Amaya, D Gagne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2021
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast CancerBryan P Schneider, Guanglong Jiang, Tarah J Ballinger, et al.
Pageof 56

Showing results (541-550 of 557) with videos related to

Sort By:
Pageof 56
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|June 2, 2005
Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophreniaG B Fox, T A Esbenshade, J B Pan, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 21, 2012
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonistTimothy A Esbenshade, Kaitlin E Browman, Thomas R Miller, et al.
Science Translational Medicine|November 19, 2016
The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicityMichal Wieczorek, Joseph Tcherkezian, Cynthia Bernier, et al.
Journal of Medicinal Chemistry|September 25, 2008
Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligandsRobert J Altenbach, Ronald M Adair, Brian M Bettencourt, et al.
Plos Computational Biology|April 23, 2020
Vector bionomics and vectorial capacity as emergent properties of mosquito behaviors and ecologySean L Wu, Héctor M Sánchez C, John M Henry, et al.
Biochemical Pharmacology|March 21, 2007
Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activityMarlon Cowart, Gregory A Gfesser, Kaitlin E Browman, et al.
Breast Cancer Research and Treatment|December 3, 2013
Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencingMilan Radovich, Susan E Clare, Rutuja Atale, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 21, 2004
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonistGerard B Fox, Timothy A Esbenshade, Jia Bao Pan, et al.
Journal of Neuroimmunology|April 13, 2010
Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosisK C O'Connor, C Lopez-Amaya, D Gagne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2021
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast CancerBryan P Schneider, Guanglong Jiang, Tarah J Ballinger, et al.
Pageof 56